Demonstration of a novel circulating anti-prostacyclin receptor antibody

Although coronary artery disease (CAD) is appreciated to be accelerated in patients with chronic spinal cord injury (SCI), the underlying mechanism of CAD in SCI remains obscure, We have recently shown that platelets from subjects with SCI develop resistance to the inhibitory effect of prostacyclin (PGI(2)) on the platelet stimulation of thrombin generation, The loss of the inhibitory effect was due to the loss of high-affinity prostanoid receptors, which may contribute to atherogenesis in SCI, Incubation of normal, non-SCI platelets in SCI plasma (n = 12) also resulted in the loss of high-affinity binding of PGI(2) (Kd(1) = 9.1 +/- 2.0 nM; n(1) = 170 +/- 32 sites per cell vs, Kd(1) = 7.2 +/- 1.1 nM; n(1) = 23 +/- 8 sites per cell), with no significant change in the low-affinity receptors (Kd(2) = 1.9 +/- 0.1 mu M; n(2) = 1,832 +/- 232 sites per cell vs, Kd(2) = 1.6 +/- 0.1 mu M; n(2) = 1,730 +/- 161 sites per cell) as determined by Scatchard analysis of the binding of [H-3]PGE(1), The loss of high-affinity PGI(2) binding led to the failure of PGI(2) to inhibit the platelet-stimulated thrombin generation, The increase of cellular cyclic AMP level, mediated through the binding of PGI(2) to low-affinity receptors in platelets, was unaffected in SCI platelets, PAGE and immunoblot of SCI plasma showed the presence of an IgG band, which specifically blocked the binding of [H-3]PGE(1) to the high-affinity PGI(2) receptors of normal platelets, PAGE of the reduced IgG band, the amino acid sequence of the novel band as a heavy chain of IgG that inhibits the binding of [H-3]PGE(1) to the high-affinity platelet PGI(2) receptor, demonstrates that the specific recognition and inhibition of high affinity PGI(2) binding to platelets was due to an anti-prostacyclin receptor antibody present in SCI plasma.